Medicamen Biotech responds to BSE inquiry on price movement
Medicamen Biotech (BSE:MEDICAMEQ) has responded to an inquiry from the Bombay Stock Exchange (BSE) regarding a recent surge in its share price. In a communication dated February 25, 2025, the company stated that the price increase is solely attributable to market conditions and that the management is not connected in any way with such increase. The company clarified that there are no undisclosed events or information that would explain the price fluctuation. Medicamen Biotech affirmed its commitment to compliance with SEBI (LODR) Regulations, 2015, and stated that it will continue to make appropriate disclosures in accordance with applicable regulations. The company also stated that it is compliant on the stock price movements. The BSE's inquiry was initiated on February 24, 2025, Ref No.: L/SURV/ONL/PV/AJ/2024-2025/2896. Medicamen Biotech is urging the BSE to take their confirmation on record.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Medicamen Biotech publishes news
Free account required • Unsubscribe anytime